Not provided
Not provided
Not provided
Not provided
Study device not available
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| DexCom, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This clinical study assesses the feasibility of implementing the inControl automated insulin delivery algorithm with Dexcom continuous glucose monitoring and a compatible insulin pump in adults with type 1 diabetes. It additionally provides pilot efficacy outcomes for interoperable automated insulin delivery.
Self-management of type 1 diabetes is challenging, efforts to optimise time spent in the target range can result in hypo- and hyperglycaemia. Structured education, glucose monitoring and advances in insulin delivery can increase time in range and reduce exposure to extremes of glucose and recent data confirm that automated insulin delivery can enable further increases in time spent in the target range of 3.9 to 10mmol/L (70 - 180mg/dL).
The inControl algorithm, developed by TypeZero technologies is embedded in the Tandem X2 insulin pump and operates with the Dexcom G6 continuous glucose sensor and transmitter in a CE-marked and commercially available system (known as Control-IQ). This system optimises time in range compared with sensor-augmented pump therapy, and the improvement was maintained when participants were further randomised to predictive low glucose suspend or automated insulin delivery. The United States Food and Drug Administration has defined interoperable standards for automated insulin delivery systems, including the iCGM designation for continuous glucose sensors, the interoperable automated glycaemic controller designation, and alternate controller enabled insulin pumps. However, while standards have been defined, to date, interoperability of automated insulin delivery components has not been demonstrated.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Automated Insulin Delivery | Experimental | The components of the automated insulin delivery system are the Dexcom G6 continuous glucose monitor (CGM), the InControl algorithm and an insulin pump (Ypsomed Ypsopump). The Dexcom G6 continuous glucose monitoring device is an approved device and is licensed to be used to inform insulin dosing decisions without confirmation. The algorithm (inControl 1.0) is approved when used embedded in the Tandem X2 insulin pump. We are using the algorithm for its intended purpose but are implementing it in a smartphone app to be installed in a compatible smartphone (Android). We are additionally assessing incremental benefit with the next software version of the algorithm. This will be the first time this updated software has been assessed in people with type 1 diabetes. The compatible insulin pump is a continuous subcutaneous insulin infusion device and is being used in line with its intended purpose, according to the manufacturer's instructions (YpsoMed Ypsopump). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| InControl | Device | Automated insulin delivery system comprising continuous glucose sensor (Dexcom G6), controller (InControl embedded in smartphone app) and insulin pump (YpsoMed Ypsopump) |
| Measure | Description | Time Frame |
|---|---|---|
| % time spent in target glucose range measured by continuous glucose monitoring (3.9-10mmol/L, 70-180mg/dL) | Consensus measure of time in range | Extracted from the final 28 days of the intervention period |
| Measure | Description | Time Frame |
|---|---|---|
| % time spent in hypoglycaemia (<3.0mmol/L, 54mg/dL) | Consensus measure of time in range | Extracted from the final 28 days of the intervention period |
| % time spent in hypoglycaemia (<3.9mmol/L, 70mg/dL) |
| Measure | Description | Time Frame |
|---|---|---|
| Direct Resource Utilisation Costs | Health economic modelling exploratory outcome | Over 12 week intervention period |
| Indirect Costs | Health economic modelling exploratory outcome |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Imperial College London, Imperial College Healthcare NHS Trust | London | W2 1PG | United Kingdom |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003922 | Diabetes Mellitus, Type 1 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Consensus measure of time in range
| Extracted from the final 28 days of the intervention period |
| % time in euglycaemia (3.9-7.8mmol/L, 70-140mg/dL) | Consensus measure of time in range | Extracted from the final 28 days of the intervention period |
| % time spent in hyperglycaemia (>10mmol/L, 180mg/dL) | Consensus measure of time in range | Extracted from the final 28 days of the intervention period |
| Number hypoglycaemic excursions (sensor glucose <3.0mmol/l for >= 20min) | Consensus measure of exposure to hypoglycaemia | Over 12 week intervention period |
| Nocturnal Severe hypoglycaemia (defined as requiring third party assistance) | Consensus measure of exposure to hypoglycaemia | Over 12 week intervention period |
| Severe hypoglycaemia (defined as requiring third party assistance) | Consensus measure of exposure to hypoglycaemia | Over 12 week intervention period |
| Glucose variability assessed by %Coefficient of Variation (%CV) | Consensus measure of glucose variability | Extracted from the final 28 days of the intervention period |
| Glucose variability assessed by Mean Absolute Glucose (MAG) | Consensus measure of glucose variability | Extracted from the final 28 days of the intervention period |
| Glucose variability assessed by Low Blood Glucose Index (LBGI) | Consensus measure of glucose variability | Extracted from the final 28 days of the intervention period |
| HbA1c | Laboratory HbA1c assessment | At end of 12 week intervention period |
| Time spent in automated insulin delivery mode | % of total time that automated insulin delivery is active | Over 12 week intervention period |
| Treatment satisfaction (DTSQ, AP acceptability) | Validated patient reported outcome | At end of 12 week intervention period |
| Gold score | Validated patient reported outcome of hypoglycaemia awareness (1-7, with greater value indicating loss of awareness) | At end of 12 week intervention period |
| Diabetes distress (DDS-17) | Validated patient reported outcome, Diabetes Distress Score 17 item, higher scores mean greater distress | At end of 12 week intervention period |
| Diabetes distress (PAID) | Validated patient reported outcome, Problem Areas In Diabetes 20 item | At end of 12 week intervention period |
| Change in total daily insulin dose (units) | Total insulin delivered by system per day | At end of 12 week intervention period |
| Change in weight (kg) | Weight in kg | At end of 12 week intervention period |
| Over 12 week intervention period |
| Productivity lost | Health economic modelling exploratory outcome | Over 12 week intervention period |
| D004700 | Endocrine System Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |